european psychiatric association

Psychopharmacology

Section committee

MOHR Pavel MOHR Pavel , Chair
Stuhec Matej Stuhec Matej, Co-Chair
BARTOVA Lucie BARTOVA Lucie, Secretary


Section mission

This Section's mission is to:

Section's mission is to present the benefits and risks of psychopharmacological treatment of mental disorders. The main activities are based on general and clinical pharmacology and their association with clinical trials and prudent medication use in daily practice. 

Section objectives

  1. To increase interest in psychopharmacology
  2. To present benefits and risks of psychopharmacological treatment
  3. To present newest psychopharmacological treatment

Annual reports

Future Activities

other meetings

Section Webinar: Evidence-Based Diagnosis and Treatment of Treatment-Resistant Depression – Update and Preview
Section Webinar: Evidence-Based Diagnosis and Treatment of Treatment-Resistant Depression – Update and Preview
27 October 2025 - 27 October 2025 / Online
Description :

Webinar Overview: Major depressive disorder (MDD) is a common psychiatric condition with a significant subset of patients experiencing treatment-resistant depression (TRD). The webinar will address diagnostic challenges, including the exclusion of pseudoresistance, and provide an overview of evidence-based pharmacological and non-pharmacological treatments, including innovative approaches.

-    Moderators: Lucie Bartova, Siegfried Kasper
-    Speakers: Georg Kranz, Pia Baldinger-Melich, Christoph Kraus
-    Duration: 90 minutes, including a Q&A session.
-    Target Audience: Clinical Psychiatrists and Neuroscientists at all career stages.